Tata Digital-backed Tata 1mg continued its strong growth trajectory in FY26, with consolidated revenue rising 23% year-on-year to ₹2,936 crore, bringing the digital healthcare platform close to the ₹3,000 crore milestone. At the same time, the company’s consolidated net loss narrowed to ₹287 crore, reflecting continued improvement in operating performance as it scaled its online pharmacy, diagnostics, and healthcare services businesses.
The latest financial performance, disclosed in the Tata Sons Annual Report, highlights Tata 1mg’s growing importance within Tata Digital’s consumer ecosystem. The company has steadily expanded its presence across online medicine delivery, diagnostics, teleconsultation, and corporate healthcare solutions while competing against players such as PharmEasy, Apollo 24/7, and Reliance-backed Netmeds.
Revenue Nears ₹3,000 Crore in FY26
Tata 1mg’s consolidated revenue increased to ₹2,936 crore in FY26 from ₹2,392 crore in FY25.
The revenue was generated through two operating entities:
- Tata 1mg Healthcare Solutions Pvt. Ltd.: ₹2,440 crore
- Tata 1mg Technologies Pvt. Ltd.: ₹496 crore
FY26 Financial Snapshot
| Metric | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Consolidated Revenue | ₹2,936 crore | ₹2,392 crore | +23% |
| Consolidated Net Loss | ₹287 crore | ₹276 crore* | — |
| Healthcare Solutions Revenue | ₹2,440 crore | ₹2,016 crore | +21% |
| Technologies Revenue | ₹496 crore | ₹376 crore | +32% |
*FY25 consolidated loss as reported previously by Entrackr.
Healthcare Business Continues to Drive Growth
The healthcare solutions business remained Tata 1mg’s largest revenue contributor.
Its operations include:
- Online pharmacy.
- Prescription medicine delivery.
- Diagnostic testing.
- Healthcare products.
- Vitamins and nutrition supplements.
- Chronic care services.
The continued expansion reflects rising adoption of digital healthcare services and increasing demand for integrated health platforms.
Mixed Profitability Across Business Units
While the core healthcare business remained loss-making, its performance improved compared with previous years.
During FY26:
- Tata 1mg Healthcare Solutions reported a ₹310 crore loss.
- Tata 1mg Technologies remained profitable with a ₹23 crore net profit.
Combined, the two entities posted a consolidated net loss of ₹287 crore.
Balance Sheet Strengthens
At the end of FY26:
- Combined assets stood at ₹2,268 crore.
- Total liabilities were ₹1,601 crore.
- Combined reserves and surplus remained negative at ₹167 crore, reflecting accumulated historical losses, although the position has improved significantly over time.
Balance Sheet Highlights
| Item | FY26 |
|---|---|
| Total Assets | ₹2,268 crore |
| Total Liabilities | ₹1,601 crore |
| Combined Reserves & Surplus | -₹167 crore |
Strategic Importance Within Tata Digital
Tata 1mg has become one of Tata Digital’s flagship consumer businesses alongside platforms such as BigBasket and Croma.
The company continues to invest in:
- Expanding diagnostics centres.
- Corporate healthcare offerings.
- Faster medicine delivery.
- Digital healthcare services beyond metro cities.
- Integration with the Tata Neu ecosystem.
The platform also benefits from increasing cross-selling opportunities across Tata Group’s digital ecosystem.
Competition Remains Intense
India’s online healthcare market continues to see strong competition from:
- Apollo 24/7
- PharmEasy
- Netmeds
- Regional digital healthcare providers.
Companies are increasingly expanding beyond medicine delivery into diagnostics, preventive healthcare, teleconsultation, subscription plans, and chronic disease management to attract and retain customers.
Looking Ahead
Tata 1mg’s FY26 performance demonstrates that the company is maintaining robust growth while steadily improving its financial profile. Crossing ₹2,900 crore in revenue reflects the continued expansion of India’s digital healthcare market, with online pharmacy, diagnostics, and integrated healthcare services driving demand. Although the platform remains loss-making on a consolidated basis, narrowing losses alongside double-digit revenue growth suggests progress toward building a more sustainable business model.
Looking ahead, Tata 1mg is expected to continue investing in diagnostics, rapid medicine delivery, corporate healthcare solutions, and deeper integration with the Tata Neu ecosystem. As competition intensifies among major healthtech players, the company’s ability to balance growth with improving profitability will be a key factor in strengthening its position in India’s fast-evolving digital healthcare sector.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
